山梨医科大学雑誌　第16巻3号　073-085(2001)


Dipyridamole Prevents Hyperbilirubinemia Caused by Intrahepatic
Cholestasis after Resection of Esophageal Cancer

Kouichirou NISHIDA

Abstract: Hyperbilirubinemia after subtotal esophagectomy, involving thoracotomy and/or laparotomy, is the most well-known type of postoperative hyperbilirubinemia.
　Dipyridamole, a drug used to treat ischemic heart disease, influences the metabolism and transport of adenosine and adenosine nucleotide, and it potentiates the action of adenosine.
　In this study, we first found that dipyridamole prevented liver dysfunction by an experiment using dogs and then performed a clinical study to evaluate the effect of preoperatively administered dipyridamole on the occurrence of hyperbilirubinemia.
　Total bilirubin (T-Bil) exceeded 2.0 mg/dl during the observation period in five patients (45.5 ％)from the dipyridamole (Persantin, Boehringer)-treated group (P group), but it exceeded 3.0 mg/dl in only two of them (maximum value: 3.46 mg/dl ). In the untreated group (NP group), however, T-Bil exceeded 2.0 mg/dl in nine patients (69.2 ％) and exceeded 3.0 mg/dl in seven of them (maxi-mum value: 6.42 mg/dl ). In the P group, direct bilirubin (D-Bil) exceeded 1.0 mg/dl in two patients (maximum value: 1.08 mg/dl ). In the NP group, it exceeded 1.0 mg/dl in seven patients (maximum value: 3.66 mg/dl ). In a comparison between the P and NP groups, the P group showed significantly lower values of both T-Bil and D-Bil (p ＜0.05).
　Dipyridamole may prevent liver dysfunction by minimizing intrahepatic cholestasis.

Key words: Dipyridamole, Hyperbilirubinemia, Intrahepatic cholestasis, Esophageal cancer, Portal blood flow




本文は、編集委員会の意向によりインターネットには公開しておりません。図書館等でご覧ください。

Texts are not availavle on Internet.



目次・Contentsに戻る